Fulcrum Therapeutics (FULC) Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Assets for 9 consecutive years, with $324.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Assets rose 41.56% year-over-year to $324.0 million; the TTM figure through Jun 2026 stood at $324.0 million (up 41.56% YoY), while the FY2025 annual figure was $366.3 million, up 40.49% from the prior year.
• Assets slipped to $324.0 million in Q2 2026 per FULC's latest filing, from $346.8 million in the prior quarter.
• Across five years, Assets topped out at $366.3 million in Q4 2025 and bottomed at $195.2 million in Q2 2022.
• Historically, Assets has averaged $268.8 million across 5 years, with a median of $259.2 million in 2023.
• Annual changes were most pronounced in 2023 — Assets soared 53.83% — and 2024, when it fell 27.57%.
• Fulcrum Therapeutics' Assets stood at $226.7 million in 2022, then grew by 13.68% to $257.7 million in 2023, then advanced by 1.17% to $260.7 million in 2024, then jumped by 40.49% to $366.3 million in 2025, then slipped by 11.56% to $324.0 million in 2026.
• Business Quant data shows FULC's Assets at $324.0 million in Q2 2026, $346.8 million in Q1 2026, and $366.3 million in Q4 2025.